SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sigyn Therapeutics, Inc.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$0.03+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $48.16K
- P/E (TTM)
- –
- Dividend yield
- –
Sigyn Therapeutics, Inc. revenue by segment
By business segment
| Revenue | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | TTM Q3 18 | TTM Q2 18 | TTM Q1 18 | TTM Q4 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wholesale Sales [Member] | $9.93K | $38.20K | $38.95K | $143.32K | $81.08K | $50.97K | $73.63K | $63.98K | $120.72K | $155.27K | $229.33K | $222.93K | 100.0% | -87.8% |
| Retail sales [Member] | $0 | $0 | $0 | $0 | $162.35K | $250.81K | $404.32K | $623.51K | $743.59K | $874.57K | $1.06M | $1.06M | 0.0% | -100.0% |
By product or service
By region
From the segment and revenue-disaggregation notes of Sigyn Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.